KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Receivables: 2017-2025

Historic Change in Receivables for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$63,000.

  • Aquestive Therapeutics' Change in Receivables fell 101.70% to -$63,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 86.03%. This contributed to the annual value of -$1.1 million for FY2024, which is 135.60% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Change in Receivables is -$63,000, which was down 104.68% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Change in Receivables peaked at $7.7 million during Q1 2022, and registered a low of -$8.2 million during Q3 2022.
  • Moreover, its 3-year median value for Change in Receivables was -$63,000 (2025), whereas its average is $581,091.
  • Its Change in Receivables has fluctuated over the past 5 years, first crashed by 2,132.69% in 2024, then skyrocketed by 2,228.57% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Change in Receivables (Quarterly) stood at -$1.4 million in 2021, then slumped by 343.92% to -$6.1 million in 2022, then spiked by 98.29% to -$104,000 in 2023, then slumped by 2,132.69% to -$2.3 million in 2024, then slumped by 101.70% to -$63,000 in 2025.
  • Its last three reported values are -$63,000 in Q3 2025, $1.3 million for Q2 2025, and $3.1 million during Q1 2025.